GSK3A and familial pancreatic carcinoma: The GSK3α/β inhibitor sensitivity of xenografts from primary and metastatic pancreatic cancer patients who progressed on chemo- and radiation therapies warrants further clinical investigation of GSK3α/β inhibitors as single agents or in combination.